Writing Testimony in Support of Accessible Labeling Laws

Providing your testimony to the committee or legislature considering a bill regarding accessible prescription labeling can influence the passage and amendment process if changes need to be made to make it achieve the desired end result.
Ideally, the collection of testimonies provided to the legislature or committee will include a wide range of experiences that demonstrate the key points the law is designed to address.  If you are part of a group, perhaps have a discussion about who will focus their testimony on which of the talking points below so the gambit of issues are addressed through the testimonies. 
The purpose of the testimony is to demonstrate how the law would assist both you and the pharmacist in more effective communication, equal access to printed prescription information required by the FDA, and provide personal safety, independence and pursuit of health and happiness. 
When writing, keep these key points in mind:
  • The difficulty of managing prescriptions without sight
  • Equal access to mandated prescription information
  • The challenge of requesting accommodation at the pharmacy
  • The (in)effectiveness of solutions already offered
  • The personal and financial cost of medication errors for patient and pharmacy

NJ Bill to Require Warnings Label on Rx Opioids Passes Senate

Legislation sponsored by Senator Kristin Corrado (R-40) in New Jersey requiring prescription opioid medications to include a warning sticker advising patients of the risk of addiction and overdose has passed the New Jersey Senate.
“New Jerseyans who are prescribed opioid medications should be aware of the potential dangers every time they reach for the bottle,” Corrado said. “The unprecedented rise in opioid deaths proves that we must do more to combat the addiction crisis. The bill we passed today is a simple step, but it will save countless lives.”
Corrado’s bipartisan bill, S-2244/A-3292, would require any prescription opioid medication dispensed in the State of New Jersey to include a warning sticker describing the risks of opioid medications. Opioids that would qualify for a label under the bill include codeine, hydrocodone (Vicodin), hydromorphone (Dilaudid), meperidine (Demerol) and oxycodone (OxyContin).

7-day Prescription Bill Proposed to Mitigate Opioid Abuse

Sens. Kirsten Gillibrand, D-N.Y. and Cory Gardner, R-Colo. announced the introduction of the John S. McCain Opioid Addiction and Prevention Act (S. 724), which would limit to a seven-day supply the initial prescriptions of opioids for acute pain. This limit would mandate what the Centers for Disease control already recommend.